CMV reactivation in allogeneic hematopoietic stem cell transplant patients receiving post-transplant cyclophosphamide.
Markowski P, Schaar D, Wei C, Tyno A. CMV reactivation in allogeneic hematopoietic stem cell transplant patients receiving post-transplant cyclophosphamide. Journal Of Clinical Oncology 2019, 37: e18533-e18533. DOI: 10.1200/jco.2019.37.15_suppl.e18533.Peer-Reviewed Original ResearchPost-transplant cyclophosphamideStem cell transplant patientsCMV reactivationCell transplant patientsPTCy groupTransplant patientsAllogeneic hematopoietic stem cell transplant patientsHematopoietic stem cell transplant patientsReactivation rateDonor CMV serostatusDonor CMV statusPost-transplant CYPrevention of graftEffective prophylactic treatmentNumber of patientsDonor serostatusTransplant cyclophosphamideCMV serostatusHost diseaseCMV statusRetrospective reviewProphylactic treatmentIncreased incidencePatient populationCMV titers
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply